tislelizumab
beigene,novartis
we're proud to have three tislelizumab abstracts accepted for poster or oral presentations at the world congress on gastrointestinal #cancer. 
Formerly @BeiGeneUSA, we're transforming the biotech industry, creating impactful medicines for patients globally. Community guidelines: https://t.co/bZCHuaXk0s